VIDEO: Fluocinolone acetonide implant shows promise for treatment of noninfectious uveitis
Click Here to Manage Email Alerts
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Danny A. Mammo, MD, presents data investigating the 0.18 mg fluocinolone acetonide implant for the treatment of noninfectious uveitis in the posterior segment.
According to Mammo, 80% of patients included in the study showed one or more recurrence of uveitis within a year prior to implantation, a number which dropped to 10% at 24 months after implantation.
“This 24-month data for the CALM study shows us that the fluocinolone acetonide implant is effective in treating noninfectious uveitis affecting the posterior segment,” he said.
Collapse
Mammo DA. CALM: 24-month outcomes from a phase 4, retrospective, real-world registry of patients with chronic non-infectious uveitis affecting the posterior segment treated with the 0.18 mg fluocinolone acetonide intravitreal insert. Presented at: Hawaiian Eye 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Read more about
Click Here to Manage Email Alerts